
McKesson (MCK) Stock Forecast & Price Target
McKesson (MCK) Analyst Ratings
Bulls say
McKesson is benefiting from a broad-based beat-and-raise, with specialty prescription volume growth, including GLP-1s, driving stronger-than-expected performance across core North American Pharma and O&M, while O&M operating income rose 23% on an adjusted basis. Its earnings power is being reinforced by operating leverage, stable end markets, and strategic acquisitions such as Precision Medicine Group, Spectrum Vision, and Option Care Health, which expand oncology, clinical research, and wraparound specialty services; management also raised adjusted EPS guidance by $1.40. With earnings growth now expected at 17-19% versus 13-16% under its long-range plan, plus >99% order accuracy and a high-growth specialty drug mix, the company appears well positioned to sustain above-peer fundamentals and long-term valuation upside.
Bears say
McKesson is facing a deteriorating risk-reward profile because its growth increasingly depends on RxTS and BioPharma Solutions just as GLP-1 prior authorizations are leveling off and employer coverage is eroding, putting roughly 9.5%-11.5% of RxTS revenue, or about $560-$660 million, at risk. Regulatory overhang is another major drag, since 2028 Part B Maximum Fair Price negotiations could cut prices by 40%-60% on about $28 billion of Medicare drug spend, threatening the specialty mix that supports differentiated returns. With core distribution margins already razor thin and competition, biosimilar steerage, and slower automation gains all pressuring margins, the company may struggle to sustain the 11-15% operating income growth target.
This aggregate rating is based on analysts' research of McKesson and is not a guaranteed prediction by Public.com or investment advice.
McKesson (MCK) Analyst Forecast & Price Prediction
Start investing in McKesson (MCK)
Order type
Buy in
Order amount
Est. shares
0 shares
FAQs About McKesson (MCK) Forecast
McKesson (MCK) Analyst Forecast & Price Prediction
Start investing in McKesson (MCK)
Order type
Buy in
Order amount
Est. shares
0 shares